ClinicalTrials.gg
CompletedNCT05266586ROSE2Updated Jul 3, 2024Results posted

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

A Phase 2 interventional study of Obicetrapib and Ezetimibe 10mg in Dyslipidemias, High Cholesterol and Hypercholesterolemia, sponsored by NewAmsterdam Pharma. Completed at 16 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-03.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
62nd of 97
119 · median 148
Started
2022
with 1 other
Phase 2
7 of 98
1 open now
Registered
92nd of 98
by date
Lead sponsor
2 of 98
NewAmsterdam Pharma

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 62nd largest by enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2022, is one of 7 in phase 2, and was the 92nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.

Read the detailed description

This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy. The screening period for this study will take up to 2-weeks. Afterwards patients will be randomized to placebo, 10 mg obicetrapib monotherapy, or 10 mg obicetrapib + 10 mg ezetimibe combination therapy for a 12-week treatment period. After the treatment period, patients will continue for a 4-week safety follow-up.

03

Conditions studied

  • Dyslipidemias
  • High Cholesterol
  • Hypercholesterolemia

Browse trials for

Keywords

  • obicetrapib
  • statin
  • LDL-C
  • cholesterol
  • atherosclerosis
04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 119 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • LDL-C > 70 mg/dL and Triglycerides \< 400 mg/dL,
  • Treated with a high-intensity statin therapy

Exclusion criteria

Exclusion Criteria:

  • >= 40 kg/m2
  • Significant cardiovascular disease
  • >= 10%
  • Uncontrolled hypertension
  • Active muscle disease
  • estimated \< 60 mL/min
  • Hepatic dysfunction
  • History of participation in any clinical trial evaluating obicetrapib
  • Anemia
  • History of
  • Alcohol abuse
  • Treatment with product
  • Treatment with PCSK9
  • condition
  • Known CETP inhibitor allergy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    once-daily placebo tablet and placebo capsule

    Other: Obicetrapib placebo · Other: Ezetimibe placebo

  • Experimental
    monotherapy

    once-daily obicetrapib 10 mg tablet and placebo capsule

    Drug: Obicetrapib · Other: Ezetimibe placebo

  • Experimental
    combination therapy

    once-daily obicetrapib 10 mg tablet and ezetimibe 10 mg capsule

    Drug: Obicetrapib · Drug: Ezetimibe 10mg

Interventions

  • tablets

    Also known as: CETP inhibitor

  • capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.

  • OtherObicetrapib placebo

    tablets; no active ingredient

  • OtherEzetimibe placebo

    capsules; no active ingredient

07

What researchers measure

Primary outcomes

  1. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]

    Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 12-weeks

  2. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]

    Median percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  3. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]

    LS Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  4. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]

    Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  5. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]

    Median percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  6. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]

    LS Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

Secondary outcomes

  1. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]

    Mean percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 12-weeks

  2. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]

    Median percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  3. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]

    LS Mean percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  4. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]

    Mean percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  5. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]

    Median percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  6. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]

    LS Mean percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

    Time frame: 12-Weeks

  7. Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo

    Mean percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg plus ezetimibe 10 mg combination treatment group compared with the placebo group

    Time frame: 12-weeks

  8. Median Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo

    Median percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg plus ezetimibe 10 mg combination treatment group compared with the placebo group

    Time frame: 12-Weeks

  9. LS Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo

    LS Mean percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg plus ezetimibe 10 mg combination treatment group compared with the placebo group

    Time frame: 12-Weeks

  10. Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo

    Mean percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

    Time frame: 12-weeks

  11. Median Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo

    Median percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

    Time frame: 12-Weeks

  12. LS Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo

    LS Mean percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

    Time frame: 12-Weeks

08

Results

Posted Jul 3, 2024

Participant flow

231 participants were screened; out of 231, 119 participants were randomized.

Participant flow — Overall Study
MilestonePlaceboMonotherapyCombination Therapy
Started403940
Completed363638
Not completed432
Withdrew: Adverse event221
Withdrew: Withdrawal by subject101
Withdrew: Non-compliance with study drug010
Withdrew: Subject unable to adhere to all protocol requirements100

Outcome measures

PrimaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]

Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
12-weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
percent change from baselinePlaceboCombination Therapy
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]-0.83 ± 24.514-59.07 ± 14.814
Statistical analysis
  • Placebo vs Combination Therapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -58.38 · 95% CI -68.59 to -48.18mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]

Median percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
percent change from baselinePlaceboCombination Therapy
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]-6.35 (-36.4 to 96.7)-63.40 (-83.7 to -29.7)
Statistical analysis
  • Placebo vs Combination Therapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -58.38 · 95% CI -68.59 to -48.18mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]

LS Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]
percent change from baselinePlaceboCombination Therapy
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]-0.85 ± 3.472-59.23 ± 3.786
Statistical analysis
  • Placebo vs Combination Therapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -58.38 · 95% CI -68.59 to -48.18mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]

Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]
percent change from baselinePlaceboCombination Therapy
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]-1.49 ± 23.762-59.51 ± 15.192
Statistical analysis
  • Placebo vs Combination Therapy · ANCOVA · p = <.0001 · Least squares (ls) means: -58.15 · 95% CI -68.47 to -47.83
PrimaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]

Median percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]
percent change from baselinePlaceboCombination Therapy
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]-3.95 (-34.3 to 91.8)-62.80 (-82.3 to -31.0)
Statistical analysis
  • Placebo vs Combination Therapy · ANCOVA · p = <.0001 · Least squares (ls) means: -58.15 · 95% CI -68.47 to -47.83
PrimaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]

LS Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]
percent change from baselinePlaceboCombination Therapy
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]-1.54 ± 3.533-59.69 ± 3.811
Statistical analysis
  • Placebo vs Combination Therapy · ANCOVA · p = <.0001 · Least squares (ls) means: -58.15 · 95% CI -68.47 to -47.83
SecondaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]

Mean percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
12-weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]
percent change from baselinePlaceboMonotherapy
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]-0.83 ± 24.514-39.35 ± 22.602
Statistical analysis
  • Placebo vs Monotherapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -38.35 · 95% CI -49.07 to -27.63mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]

Median percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]
percent change from baselinePlaceboMonotherapy
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]-6.35 (-36.4 to 96.7)-43.50 (-78.4 to 22.6)
Statistical analysis
  • Placebo vs Monotherapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -38.35 · 95% CI -49.07 to -27.63mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]

LS Mean percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C was calculated using the Friedewald equation unless TG ≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]
percent change from baselinePlaceboMonotherapy
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [Friedewald]-0.85 ± 3.472-39.20 ± 4.133
Statistical analysis
  • Placebo vs Monotherapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -38.35 · 95% CI -49.07 to -27.63mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]

Mean percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]
percent change from baselinePlaceboMonotherapy
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]-1.49 ± 23.762-39.04 ± 23.456
Statistical analysis
  • Placebo vs Monotherapy · ANCOVA · p = <.0001 · Least squares (ls) means: -37.21 · 95% CI -48.07 to -26.35
SecondaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]

Median percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]
percent change from baselinePlaceboMonotherapy
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]-3.95 (-34.3 to 91.8)-43.55 (-78.4 to 20.4)
Statistical analysis
  • Placebo vs Monotherapy · ANCOVA · p = <.0001 · Least squares (ls) means: -37.21 · 95% CI -48.07 to -26.35
SecondaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]

LS Mean percent change in Low-Density Lipoprotein Cholesterol (LDL-C) from day 1 to day 84 for obicetrapib 10 mg monotherapy treatment group compared with the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).

Time frame:
12-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]
percent change from baselinePlaceboMonotherapy
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Obicetrapib 10 mg Monotherapy Compared With Placebo [PUC]-1.54 ± 3.533-38.75 ± 4.166
Statistical analysis
  • Placebo vs Monotherapy · ANCOVA · p = <.0001 · Least squares (ls) means: -37.21 · 95% CI -48.07 to -26.35
SecondaryMean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo

Mean percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg plus ezetimibe 10 mg combination treatment group compared with the placebo group

Time frame:
12-weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo
percent change from baselinePlaceboCombination Therapy
Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo0.51 ± 19.784-34.66 ± 11.796
Statistical analysis
  • Placebo vs Combination Therapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -35.68 · 95% CI -43.23 to -28.13mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo

Median percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg plus ezetimibe 10 mg combination treatment group compared with the placebo group

Time frame:
12-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo
percent change from baselinePlaceboCombination Therapy
Median Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo-2.05 (-30.9 to 76.9)-34.40 (-54.3 to -14.7)
Statistical analysis
  • Placebo vs Combination Therapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -35.68 · 95% CI -43.23 to -28.13mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo

LS Mean percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg plus ezetimibe 10 mg combination treatment group compared with the placebo group

Time frame:
12-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo
percent change from baselinePlaceboCombination Therapy
LS Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib in Combination With Ezetimibe Compared to Placebo0.72 ± 2.572-34.95 ± 2.796
Statistical analysis
  • Placebo vs Combination Therapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -35.68 · 95% CI -43.23 to -28.13mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo

Mean percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

Time frame:
12-weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo
percent change from baselinePlaceboMonotherapy
Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo0.51 ± 19.784-21.73 ± 16.057
Statistical analysis
  • Placebo vs Monotherapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -22.28 · 95% CI -30.21 to -14.36mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo

Median percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

Time frame:
12-Weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo
percent change from baselinePlaceboMonotherapy
Median Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo-2.05 (-30.9 to 76.9)-24.20 (-44.8 to 27.1)
Statistical analysis
  • Placebo vs Monotherapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -22.28 · 95% CI -30.21 to -14.36mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo

LS Mean percent change from day 1 to day 84 in Apolipoprotein-B (ApoB) for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

Time frame:
12-Weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo
percent change from baselinePlaceboMonotherapy
LS Mean Percent Change in Apolipoprotein-B (ApoB) for Obicetrapib 10 mg Monotherapy Compared With Placebo0.72 ± 2.572-21.56 ± 3.052
Statistical analysis
  • Placebo vs Monotherapy · Mixed Models Analysis · p = <.0001 · Least squares (ls) means: -22.28 · 95% CI -30.21 to -14.36mixed model for repeated measures (MMRM) with missing at random assumption

Adverse events

Collected over From first dose of study drug through Week 16. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/40 (0%)1/40 (2.5%)16/40 (40%)
Monotherapy0/39 (0%)1/39 (2.6%)8/39 (20.5%)
Combination Therapy0/40 (0%)0/40 (0%)11/40 (27.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboMonotherapyCombination Therapy
Acute myocardial infarctionCardiac disorders0/401/390/40
Cerebrovascular accidentNervous system disorders1/400/390/40
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPlaceboMonotherapyCombination Therapy
Urinary tract infectionInfections and infestations2/400/391/40
NauseaGastrointestinal disorders2/400/392/40
HeadacheNervous system disorders2/401/390/40
MyalgiaMusculoskeletal and connective tissue disorders2/400/390/40
COVID-19Infections and infestations0/401/391/40
Abdominal painGastrointestinal disorders0/401/390/40
Abdominal pain upperGastrointestinal disorders0/401/390/40
Foot fractureInjury, poisoning and procedural complications0/401/391/40
Muscle strainInjury, poisoning and procedural complications1/401/390/40
Vaccination complicationInjury, poisoning and procedural complications0/401/390/40

Baseline characteristics

Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.

Age, Continuous
Age, Continuous(years)PlaceboMonotherapyCombination TherapyTotal
Mean60.6 ± 8.4664.8 ± 7.2463.5 ± 9.0862.6 ± 8.48
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMonotherapyCombination TherapyTotal
Female1491235
Male26171962
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMonotherapyCombination TherapyTotal
Hispanic or Latino4239
Not Hispanic or Latino35242887
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMonotherapyCombination TherapyTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American93214
White30232982
More than one race0000
Unknown or Not Reported0000
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values(milligrams per deciliter (mg/dL))PlaceboMonotherapyCombination TherapyTotal
Mean99.1 ± 27.06100.6 ± 33.6596.0 ± 25.6298.57 ± 28.78
09

Study locations

16 sites
  • Velocity Clinical Research - Westlake d.b.a National Research Institute
    Los Angeles, California 90057, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Ocala Cardiovascular Research
    Ocala, Florida 34471, United States
  • A & R Research Group, LLC
    Pembroke Pines, Florida 33024, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Meridian Clinical Research - Savannah, GA
    Savannah, Georgia 31406, United States
  • Velocity Clinical Research
    Meridian, Idaho 83642, United States
  • Biofortis, Inc
    Addison, Illinois 60101, United States
  • Northwest Heart Clinical Research, LLC
    Arlington Heights, Illinois 60005, United States
  • Midwest Institute for Clinical Research
    Indianapolis, Indiana 46260, United States
  • Research Integrity LLC
    Owensboro, Kentucky 42303, United States
  • Oakland Medical Research Center
    Troy, Michigan 48085, United States
  • Mercury Street Medical
    Butte, Montana 59701, United States
  • Meridian Clinical Research- Springdale, OH
    Cincinnati, Ohio 45219, United States
  • Aventiv Research, Inc.
    Columbus, Ohio 43213, United States
  • Summit Research Group, LLC
    Munroe Falls, Ohio 44240, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Aug 2022, 5 months.

Results were first posted in Jul 2024, 1 year 10 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 5 months is below that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2022
First posted
Mar 4, 2022
StartActual
Mar 9, 2022
Primary completionActual
Aug 12, 2022
CompletionActual
Sep 8, 2022
Results first posted
Jul 3, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05266586
Lead sponsor
NewAmsterdam Pharma
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Mar 9, 2022
Primary completion
Aug 12, 2022
Completion
Sep 8, 2022
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Study contacts

Marc Ditmarsch
study director · NewAmsterdam Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TA-8995 · Ezetimibe

Start the discussion